Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 9/20 | 0.36 |
| ▸ | MMP9 | P14780 | 9/20 | 0.36 |
| ▸ | MMP14 | P50281 | 7/20 | 0.36 |
| ▸ | MMP8 | P22894 | 2/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.32 |
| ▸ | RELA | Q04206 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14727673 | 0.96 | KMT2A (0.44) | KMT2AATMELANEADORA3MMP2 | |
| SCHEMBL14727678 | 0.89 | THRB (0.42) | KMT2AATMELANEADORA3NFKB1 | |
| SCHEMBL14727672 | 0.89 | KMT2A (0.40) | KMT2AATMELANEADORA3NFKB1 | |
| SCHEMBL14727711 | 0.87 | THRB (0.37) | KMT2AATMELANEADORA3MMP2 | |
| SCHEMBL14727706 | 0.86 | THRB (0.40) | KMT2AATMELANEADORA3MMP2 | |
| SCHEMBL14727703 | 0.86 | GPR119 (0.36) | KMT2AATMELANEADORA3MMP2 | |
| SCHEMBL14727681 | 0.85 | KMT2A (0.40) | KMT2AATMELANEADORA3MAPT | |
| SCHEMBL14727679 | 0.85 | HTT (0.50) | KMT2AATMELANENFKB1NFKB2 | |
| SCHEMBL14727710 | 0.85 | POLB (0.46) | KMT2ANFKB1NFKB2RELAMEN1 | |
| SCHEMBL14727675 | 0.84 | KMT2A (0.39) | KMT2AATMELANEADORA3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8840807-B2 | Polymerizable compound | JNC CORPORATION (JP) | 2014-09-23 | — | — | US | disclosed |
| US-8840807-B2 | Polymerizable compound | JNC CORPORATION (JP) | 2014-09-23 | — | — | US | disclosed |
| US-20130048912-A1 | POLYMERIZABLE COMPOUND | JNC PETROCHEMICAL CORPORATION (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130048912-A1 | POLYMERIZABLE COMPOUND | JNC PETROCHEMICAL CORPORATION (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130048912-A1 | POLYMERIZABLE COMPOUND | PYM1, ZYX, CPNE4 | KMT2A 617/4885ATM 2670/4885ELANE 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.